A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

BACKGROUND: PHI-101 is an orally available, selective checkpoint kinase 2 (Chk2) inhibitor. PHI-101 has shown anti-tumour activity in ovarian cancer cell lines and impaired DNA repair pathways in preclinical experiments. Furthermore, the in vivo study suggests the synergistic effect of PHI-101 throu...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Soo Jin, Chang, Suk-Joon, Suh, Dong Hoon, Kong, Tae Wook, Song, Heekyoung, Kim, Tae Hun, Kim, Jae-Weon, Kim, Hee Seung, Lee, Sung-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722005/
https://www.ncbi.nlm.nih.gov/pubmed/34980026
http://dx.doi.org/10.1186/s12885-021-09138-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722005/
https://www.ncbi.nlm.nih.gov/pubmed/34980026
http://dx.doi.org/10.1186/s12885-021-09138-z

Ejemplares similares